Literature DB >> 6538707

Endocrine effects of tamoxifen in postmenopausal breast cancer patients.

F Boccardo, D Guarneri, A Rubagotti, G L Casertelli, G Bentivoglio, N Conte, G Campanella, G Gaggero, G Comelli, S Zanardi.   

Abstract

The effects of tamoxifen on plasma concentration of gonadotropins, prolactin (PRL), estrone (E1), estradiol-17 beta (E2), and sex hormone-binding globulin (SHBG) were studied in 40 postmenopausal breast cancer patients. In addition, the changes induced by the drug on endometrium and vaginal epithelium were investigated. After 6-8 weeks of tamoxifen treatment, a significant decrease in FSH, LH and PRL basal levels was observed, whereas the concentrations of E1 and E2 were not significantly affected. A significant increase in SHBG levels was induced by prolonged treatment with the drug. In addition, tamoxifen caused a partial estrogenization of vaginal smears, and a weak stimulatory effect on endometrium was also apparent. These findings indicate that tamoxifen produced agonistic effects on some targets and antagonistic effects on the others.

Entities:  

Mesh：

Substances：

Year:  1984        PMID： 6538707     DOI： 10.1177/030089168407000110

Source DB:  PubMed          Journal:  Tumori        ISSN： 0300-8916


  14 in total

1.  Suppression of Estrogenic Activity by Medroxyprogesterone Acetate in Tamoxifen-treated Patients after Surgery for Breast Cancer to Reduce the Risk of Endometrial Cancer Development.

Authors: 
Journal:  Breast Cancer       Date:  1996-03-29       Impact factor: 4.239

2.  Effects of tamoxifen on bone mineral density and metabolism in postmenopausal women with early-stage breast cancer.

Authors:  Jamal Zidan; Zohar Keidar; Walid Basher; Ora Israel
Journal:  Med Oncol       Date:  2004       Impact factor: 3.064

3.  Effects of experimental chemoendocrine therapy with a combination of a pure antiestrogen and 5-fluorouracil on human breast cancer cells implanted in nude mice.

Authors:  Y Ogasawara; H Doihara; K Shiroma; Y Kanaya; N Shimizu
Journal:  Surg Today       Date:  1999       Impact factor: 2.549

Review 4.  Tamoxifen: a review of pharmacoeconomic and quality-of-life considerations for its use as adjuvant therapy in women with breast cancer.

Authors:  H M Bryson; G L Plosker
Journal:  Pharmacoeconomics       Date:  1993-07       Impact factor: 4.981

5.  Alternating tamoxifen and medroxyprogesterone acetate in postmenopausal advanced breast cancer patients--short and long term endocrine effects.

Authors:  L Canobbio; E Galligioni; G Gasparini; T Fassio; D Crivellari; D Villalta; G Santini; S Monfardini; F Boccardo
Journal:  Breast Cancer Res Treat       Date:  1987-11       Impact factor: 4.872

Review 6.  Tamoxifen and secondary tumours. An update.

Authors:  N Wilking; E Isaksson; E von Schoultz
Journal:  Drug Saf       Date:  1997-02       Impact factor: 5.606

Review 7.  Gynecologic effects of tamoxifen: case reports and review of the literature.

Authors:  R M Caputo; L J Copeland
Journal:  Int Urogynecol J Pelvic Floor Dysfunct       Date:  1996

8.  Pathology of endometrium treated with tamoxifen.

Authors:  S M Ismail
Journal:  J Clin Pathol       Date:  1994-09       Impact factor: 3.411

Review 9.  Tamoxifen. A reappraisal of its pharmacodynamic and pharmacokinetic properties, and therapeutic use.

Authors:  M M Buckley; K L Goa
Journal:  Drugs       Date:  1989-04       Impact factor: 9.546

Review 10.  Tamoxifen as adjuvant therapy in breast cancer. Current status.

Authors:  P N Plowman
Journal:  Drugs       Date:  1993-11       Impact factor: 9.546
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.